A61K 2239/48
Blood cells
Official title: Blood cells, e.g. leukemia or lymphoma
A61K2239/48 (Blood cells) appears on 1,057 US grants and 2,646 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,057
- Published applications
- 2,646
- Assignees
- 816
- Inventors
- 4,120
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 5 | 0 |
| 1999 | 4 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 4 |
| 2002 | 4 | 12 |
| 2003 | 9 | 12 |
| 2004 | 6 | 19 |
| 2005 | 1 | 11 |
| 2006 | 3 | 13 |
| 2007 | 1 | 13 |
| 2008 | 7 | 7 |
| 2009 | 5 | 13 |
| 2010 | 6 | 14 |
| 2011 | 14 | 18 |
| 2012 | 7 | 16 |
| 2013 | 8 | 22 |
| 2014 | 11 | 29 |
| 2015 | 12 | 35 |
| 2016 | 18 | 56 |
| 2017 | 28 | 70 |
| 2018 | 31 | 103 |
| 2019 | 46 | 181 |
| 2020 | 100 | 261 |
| 2021 | 99 | 300 |
| 2022 | 80 | 312 |
| 2023 | 113 | 305 |
| 2024 | 122 | 348 |
| 2025 | 169 | 275 |
| 2026 | 138 | 197 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- CD5 chimeric antigen receptor for adoptive T cell therapy29 Sep 2026US 12,746,273 B2Baylor College of Medicine
- Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders29 Sep 2026US 12,747,277 B2AvenCell Europe GmbH
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Chimeric antigen receptor t cells and methods of use thereof8 Oct 2026US 2026/0308521 A1Augusta University Research Institute, Inc.
- Chimeric cytokine receptors and methods of use thereof1 Oct 2026US 2026/0294970 A1Legend Biotech USA Inc.
- Car-t cell targeting cll1, preparation method therefor and use thereof1 Oct 2026US 2026/0297519 A1Carbiogene Therapeutics Co., Ltd.
- Populations of enriched regulatory t cells and methods for producing same1 Oct 2026US 2026/0297523 A1Cellenkos, Inc.
Most cited
By later US patents
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014
- CD19-specific chimeric T cell receptor231US 7,446,179 B2City of Hope · 2008
- Methods for treatment of cancer216US 8,916,381 B1The Trustees of the University of Pennyslvania · 2014